A Phase 3 interventional study of fexofenadine HCL (M016455) and pseudoephedrine in Rhinitis Seasonal, sponsored by Sanofi. Completed at 3 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2013-10-16.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary Objective:
Secondary Objectives:
The study duration for each patient is 3 weeks and 3 days:
246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.
This study's enrollment of 520 is above the median of 80 across 187 interventional studies indexed under Rhinitis.
Browse Rhinitis studies →Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
At the start of the placebo lead-in period:
The last 3 days of the lead-in period:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study medications is administered one hour before or two hours after a meal twice a day. Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) Double-blind treatment period: 1 tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg /pseudoephedrine 60 mg (fixe dose combination)
Drug: fexofenadine HCL (M016455) · Drug: pseudoephedrine · Drug: fexofenadine HCL matching placebo · Drug: pseudoephedrine matching placebo
Study medications is administered one hour before or two hours after a meal twice a day. Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination Double-blind treatment period: 1 tablet of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 60 mg / pseudoephedrine 60 mg (fixe dose combination)
Drug: fexofenadine HCL (M016455) · Drug: pseudoephedrine · Drug: fexofenadine HCL matching placebo · Drug: pseudoephedrine matching placebo
Study medications is administered one hour before or two hours after a meal twice a day. Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) Double-blind treatment period: 2 tablets of fexofenadine 30 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 30 mg
Drug: fexofenadine HCL (M016455) · Drug: pseudoephedrine · Drug: fexofenadine HCL matching placebo
Pharmaceutical form:tablet Route of administration: oral
Pharmaceutical form:tablet Route of administration: oral
Pharmaceutical form:tablet Route of administration: oral
Pharmaceutical form:tablet Route of administration: oral
Changes in the nasal congestion score based on the patient's symptom diary
Time frame: over 2 treatment weeks (from baseline to end of treatment)
Changes in the total score of 4 symptoms, each nasal symptom (sneezing, rhinorrhea, and nasal congestion) and eye symptom
Time frame: over 2 treatment weeks (from baseline to end of treatment)
Changes in total score of 4 symptoms on a daily, day-time, and night-time bases
Time frame: over 2 treatment weeks (from baseline to end of treatment)
Changes in each symptom (sneezing, rhinorrhea, nasal congestion, and eye symptoms) score and the daily activity impairment score
Time frame: over 2 treatment weeks (from baseline to end of treatment)
Changes in each symptom score and the daily activity impairment score on a daily, day-time and night-time basis
Time frame: over 2 treatment weeks (from baseline to end of treatment)
Nasal findings
Time frame: over 2 treatment weeks (from baseline to end of treatment)
Patient's impression
Time frame: over 2 treatment weeks (from baseline to end of treatment)
Patient's safety
Time frame: over 2 treatment weeks (from baseline to end of treatment)
The record gives a start of Feb 2011, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fexofenadine · Pseudoephedrine